| Health / Medical Topics |
MEK Inhibitor GDC-0623
An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers. (NCI Thesaurus)
YOU MAY ALSO LIKE
An agent that inhibits both mitogen-activated protein kinase kinases 1 and 2 (MEK1 and MEK2), substrates of Raf and phosphorylates extracellular signal-regulated…
An orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor AZD8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or…
A substance being studied in the treatment of several types of cancer. MEK inhibitor AZD6244 blocks proteins needed for cell growth and…
An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase (MAP2K, MAPK/ERK kinase, or MEK) 1 and 2 with potential antineoplastic…
One of numerous oval bodies found in the papillae of the skin, especially those of the fingers and toes; they consist of…
Human MEIS2 wild-type allele is located in the vicinity of 15q14 and is approximately 212 kb in length. This allele, which encodes…
